Discussion from metabolism to fatty liver disease: rethinking the origin of disease and the endpoint of new drugs or metabolic dysfunction-associated steatotic liver disease
10.3760/cma.j.cn501113-20230815-00057
- VernacularTitle:从代谢谈脂肪性肝病：疾病本源与新药终点再思考
- Author:
Feng XUE
1
;
Lai WEI
Author Information
1. 清华大学附属北京清华长庚医院肝胆胰中心 清华大学临床医学院，北京 102218
- Keywords:
Fatty liver disease;
Clinical outcome;
New drug
- From:
Chinese Journal of Hepatology
2023;31(8):785-788
- CountryChina
- Language:Chinese
-
Abstract:
The diagnosis of nonalcoholic fatty liver disease (NAFLD) is an exclusionary diagnosis, and the name does not reflect the disease’s nature or mechanism. Internationally, MAFLD (metabolic dysfunction-associated fatty liver disease) and MASLD (metabolic dysfunction-associated steatotic liver disease) have recently been proposed, which are translated as metabolic dysfunction-associated fatty liver disease in Chinese. The new name reflects the initiating factors of the disease, its occurrence and development process, and the clinical significance of associated outcomes. Through interventions against metabolic disorders, liver disease (hepatic manifestations of systemic disease) reflecting MASLD (MAFLD) has the potential to improve clinical outcomes.
